The REPRIEVE study is primarily supported by the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung and Blood Institute (NHLBI) with additional financing from the NIH Office of AIDS Research. The research study was conducted by the AIDS Clinical Trials Group (ACTG).
Decades of research study and advances in HIV treatment have actually drastically lowered AIDS-related issues and deaths. As people with HIV live longer, premature heart illness and other chronic conditions have become leading reasons for morbidity and death, adding to relentless gaps in lifespan between people with HIV and the more comprehensive population.
” The REPRIEVE study reflects the evolution of HIV science, and progress from focusing mostly on approaches to treat and manage the virus to discovering ways to enhance the general health of people coping with HIV,” said acting NIAID Director Hugh Auchincloss, M.D. “These brand-new data recommend that a typical cholesterol-lowering medicine might significantly improve cardiovascular results in people with HIV.”
Statins are a class of medications consistently recommended to lower cholesterol and are known to avoid heart disease in those at risk in the basic population. It was not clear if statins would have the exact same effect in individuals dealing with HIV and who have premature heart disease regardless of having low-to-moderate conventional risk. In the REPRIEVE trial, individuals were randomly assigned to receive a daily dosage of 4 mg of pitavastatin or placebo. They were kept track of for major adverse negative responses and cardiovascular occasions to pitavastatin, which is thought about safe for usage with all recommended antiretroviral treatment routines.
The studys DSMB satisfied at planned intervals throughout the study to review safety and efficacy data. In its most recent conference, the DSMB identified that the advantages of daily pitavastatin usage surpassed any risks and suggested that the research study end early, and that a full information collection be performed across sites for final analysis.
” These newest findings represent the culmination of an unprecedented eight-year effort to generate proof that can help clinicians better support the distinct cardiovascular health requirements of people coping with HIV,” said NHLBI Director Gary H. Gibbons, M.D. “REPRIEVE is essential due to the fact that there are restricted existing interventions to help prevent unfavorable cardiovascular outcomes in this population.”
Pamela Douglas, M.D., the Ursula Geller Professor of Research in Cardiovascular Diseases in the Duke University Department of Medicine, was co-principal detective of the Clinical Coordinating. Michael T. Lu, M.D., co-director of the Massachusetts General Hospital Cardiovascular Imaging Research Center, and Heather Ribaudo, Ph.D., a principal research study researcher at the Center for Biostatistics in AIDS Research and the Department of Biostatistics at Harvard University, served as leads of the REPRIEVE research studys Data Coordinating.
The National Institutes of Health (NIH) stopped a scientific trial early after finding that everyday statin medication significantly decreased cardiovascular disease threat in people coping with HIV. The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study exposed that participants taking pitavastatin calcium reduced their danger of significant unfavorable cardiovascular occasions by 35% compared to those on a placebo. The research study included 7,769 volunteers aged 40 to 75 from 12 countries, all of whom were taking antiretroviral treatment and had low-to-moderate heart disease threat. The trials Data Safety and Monitoring Board advised early termination due to compelling evidence, and the NIH accepted this suggestion. The findings could lead to a common cholesterol-lowering medication improving cardiovascular outcomes for people with HIV.
The NIH stopped a clinical trial early after discovering that daily statin medication, pitavastatin calcium, decreased cardiovascular illness threat in individuals living with HIV by 35%. The findings could cause improved cardiovascular results for this population using common cholesterol-lowering medicines.
A National Institutes of Health (NIH) medical trial was stopped early because a daily statin medication was found to reduce the increased threat of cardiovascular illness amongst individuals living with HIV in the very first massive clinical study to evaluate a main cardiovascular avoidance strategy in this population. A scheduled interim analysis of information from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) research study found that individuals who took pitavastatin calcium, a day-to-day statin, decreased their risk of major unfavorable cardiovascular events by 35% compared with those receiving a placebo.
REPRIEVE started in 2015 and registered 7,769 volunteers who were 40 to 75 years of age, of whom more than 30% were ladies. REPRIEVE volunteers were all taking antiretroviral treatment, with CD4+ cell counts higher than 100 cells/mm3 of blood at registration, and had low-to-moderate conventional heart disease danger that would not normally be thought about for statin treatment. The trial was performed in 12 countries in Asia, Europe, North America, South America, and Africa.
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study revealed that individuals taking pitavastatin calcium reduced their risk of major adverse cardiovascular occasions by 35% compared to those on a placebo. The study involved 7,769 volunteers aged 40 to 75 from 12 countries, all of whom were taking antiretroviral treatment and had low-to-moderate cardiovascular illness danger. A National Institutes of Health (NIH) medical trial was stopped early because a daily statin medication was found to lower the increased risk of cardiovascular illness amongst people living with HIV in the first massive medical research study to check a main cardiovascular prevention method in this population. A planned interim analysis of data from the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) research study discovered that individuals who took pitavastatin calcium, a daily statin, reduced their threat of significant negative cardiovascular events by 35% compared with those getting a placebo. Michael T. Lu, M.D., co-director of the Massachusetts General Hospital Cardiovascular Imaging Research Center, and Heather Ribaudo, Ph.D., a primary research scientist at the Center for Biostatistics in AIDS Research and the Department of Biostatistics at Harvard University, served as leads of the REPRIEVE research studys Data Coordinating.
